rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
11
|
pubmed:dateCreated |
1996-12-20
|
pubmed:abstractText |
The purpose of the study is to compare the clinical efficacy and safety of ciprofloxacin ophthalmic solution 0.3% (Ciloxan) with a standard therapy regimen (fortified tobramycin, 1.3%-cefazolin, 5.0%) for treating bacterial corneal ulcers.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0161-6420
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
103
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1854-62; discussion 1862-3
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8942881-Adolescent,
pubmed-meshheading:8942881-Adult,
pubmed-meshheading:8942881-Aged,
pubmed-meshheading:8942881-Aged, 80 and over,
pubmed-meshheading:8942881-Anti-Bacterial Agents,
pubmed-meshheading:8942881-Anti-Infective Agents,
pubmed-meshheading:8942881-Bacteria,
pubmed-meshheading:8942881-Cefazolin,
pubmed-meshheading:8942881-Cephalosporins,
pubmed-meshheading:8942881-Child,
pubmed-meshheading:8942881-Ciprofloxacin,
pubmed-meshheading:8942881-Cornea,
pubmed-meshheading:8942881-Corneal Ulcer,
pubmed-meshheading:8942881-Double-Blind Method,
pubmed-meshheading:8942881-Drug Therapy, Combination,
pubmed-meshheading:8942881-Eye Infections, Bacterial,
pubmed-meshheading:8942881-Female,
pubmed-meshheading:8942881-Humans,
pubmed-meshheading:8942881-Male,
pubmed-meshheading:8942881-Middle Aged,
pubmed-meshheading:8942881-Ophthalmic Solutions,
pubmed-meshheading:8942881-Prospective Studies,
pubmed-meshheading:8942881-Tobramycin
|
pubmed:year |
1996
|
pubmed:articleTitle |
Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group.
|
pubmed:affiliation |
Medical College of Wisconsin, Milwaukee, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|